Cargando…

Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen

Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, E., Obi, C.L., Nchabeleng, M., de Villiers, B.E., Sein, P.P., Letsoalo, T., Hoosen, A.A., Bessong, P.O., Ndip, R.N.
Formato: Texto
Lenguaje:English
Publicado: International Centre for Diarrhoeal Disease Research, Bangladesh 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975841/
https://www.ncbi.nlm.nih.gov/pubmed/20214081
_version_ 1782190962119802880
author Green, E.
Obi, C.L.
Nchabeleng, M.
de Villiers, B.E.
Sein, P.P.
Letsoalo, T.
Hoosen, A.A.
Bessong, P.O.
Ndip, R.N.
author_facet Green, E.
Obi, C.L.
Nchabeleng, M.
de Villiers, B.E.
Sein, P.P.
Letsoalo, T.
Hoosen, A.A.
Bessong, P.O.
Ndip, R.N.
author_sort Green, E.
collection PubMed
description Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB were tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the MGIT 960 instrument. Two hundred and nine (30.2%) strains were resistant to one or more drugs. Resistance to one drug ranged from 1.4% for ethambutol to 17.7% for rifampicin. The prevalence of MDR-TB ranged from 6.7% for three drugs to 34% for four drugs, with significant predictors being patients’ age-groups of 25–54 years (p=0.0012) and >55 years (p=0.007). The result showed a high level (58.4%) of MDR-TB from cases in Mpumalanga province. To achieve a higher cure rate in this province, drug-susceptibility tests must be done for every case.
format Text
id pubmed-2975841
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher International Centre for Diarrhoeal Disease Research, Bangladesh
record_format MEDLINE/PubMed
spelling pubmed-29758412010-12-06 Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen Green, E. Obi, C.L. Nchabeleng, M. de Villiers, B.E. Sein, P.P. Letsoalo, T. Hoosen, A.A. Bessong, P.O. Ndip, R.N. J Health Popul Nutr Original Papers Multidrug-resistant tuberculosis (MDR-TB) has been a cause of concern in both developed and developing countries. The prevalence of drug resistance in Mycobacterium tuberculosis (MTB) isolates (n=692) from Mpumalanga province was assessed. In total, 692 (64%) MTB strains from cases with pulmonary TB were tested for susceptibility against rifampicin, isoniazid, ethambutol, and streptomycin using the MGIT 960 instrument. Two hundred and nine (30.2%) strains were resistant to one or more drugs. Resistance to one drug ranged from 1.4% for ethambutol to 17.7% for rifampicin. The prevalence of MDR-TB ranged from 6.7% for three drugs to 34% for four drugs, with significant predictors being patients’ age-groups of 25–54 years (p=0.0012) and >55 years (p=0.007). The result showed a high level (58.4%) of MDR-TB from cases in Mpumalanga province. To achieve a higher cure rate in this province, drug-susceptibility tests must be done for every case. International Centre for Diarrhoeal Disease Research, Bangladesh 2010-02 /pmc/articles/PMC2975841/ /pubmed/20214081 Text en © INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Green, E.
Obi, C.L.
Nchabeleng, M.
de Villiers, B.E.
Sein, P.P.
Letsoalo, T.
Hoosen, A.A.
Bessong, P.O.
Ndip, R.N.
Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title_full Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title_fullStr Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title_full_unstemmed Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title_short Drug-susceptibility Patterns of Mycobacterium tuberculosis in Mpumalanga Province, South Africa: Possible Guiding Design of Retreatment Regimen
title_sort drug-susceptibility patterns of mycobacterium tuberculosis in mpumalanga province, south africa: possible guiding design of retreatment regimen
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2975841/
https://www.ncbi.nlm.nih.gov/pubmed/20214081
work_keys_str_mv AT greene drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT obicl drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT nchabelengm drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT devilliersbe drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT seinpp drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT letsoalot drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT hoosenaa drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT bessongpo drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen
AT ndiprn drugsusceptibilitypatternsofmycobacteriumtuberculosisinmpumalangaprovincesouthafricapossibleguidingdesignofretreatmentregimen